Ginkgo Bioworks Q1 revenue falls 49% on restructuring

Ginkgo Bioworks Holdings

07/05/2026 21:58

Overview

Synthetic biology platform's Q1 revenue fell 49% yr/yr, driven by program rationalization

Q1 adjusted EBITDA loss narrowed slightly from prior year

Company completed divestiture of Biosecurity business, now focused on autonomous lab growth

Outlook

Ginkgo reaffirms expected 2026 total cash burn of $(150)-$(125) mln

Company aims to double the size of its Nebula autonomous lab in 2026

Ginkgo expects faster adoption of autonomous labs replacing manual lab work

Result Drivers

PROGRAM RATIONALIZATION - Co said revenue decline was primarily due to ongoing program rationalization as part of restructuring activities

AUTONOMOUS LAB FOCUS - Co highlighted continued investment in scaling its autonomous lab platform, Nebula, and aims to double its size in 2026

CLOUD LAB TRACTION - Co reported traction with Cloud Lab offering through partnerships with companies such as ProQR and Amazon

Company press release: ID:nPn8DthVXa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Net Income
-$82.59 mln
Q1 Operating Expenses
$90.85 mln
Q1 Operating Income
-$71.37 mln


Analyst Coverage

The current average analyst rating on the shares is "sell" and the breakdown of recommendations is 1 "strong buy" or "buy", no "hold" and 2 "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for Ginkgo Bioworks Holdings Inc is $9.00, about 10.7% below its May 6 closing price of $10.08

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)